Progesterone for hot flush and night sweat treatment effectiveness for severe vasomotor symptoms and lack of withdrawal rebound

Gynecological Endocrinology

Volumn 28, Issue SUPPL. 2, 2012, Pages 7-11

  Prior, Jerilynn C ^a   Hitchcock, Christine L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiovascular disease; Hot flushes; Insomnia; Night sweats; Postmenopause; Progesterone; Social stress; Withdrawal syndrome

Indexed keywords

PLACEBO; PROGESTERONE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; NIGHT SWEAT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BRITISH COLUMBIA; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MIDDLE AGED; PARASOMNIAS; POSTMENOPAUSE; PROGESTERONE; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; SWEATING; VASOMOTOR SYSTEM;

EID: 84866542615     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.705390     Document Type: Article

References (34)

1. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms-a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012; DOI: 10.1097/gme.0b013e318247f07a.
2. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)-Clinical/Medical. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. 2003. Available: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ UCM135338.pdf. Accessed 26 Apr 2012.
3. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difculty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233-1239.
4. Ness J, Aronow WS, Beck G. Menopausal symptoms afer cessation of hormone replacement therapy. Maturitas 2006;53:356-361.
5. Gangar KF, Cust MP, Whitehead MI. Symptoms of oestrogen defciency associated with supraphysiological plasma estradiol concentrations in women with oestradiol implants. Br Med J 1993;299:601-602.
6. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, et al. Symptom experience afer discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
7. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Jofe H, Carpenter JS, et al. Efcacy of escitalopram for hot fashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274.
8. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109:588-596.
9. Archer DF; EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003;10:516-521.
10. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989;73:606-612.
11. Prior JC, Nielsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized doubleblind trial following premenopausal ovariectomy. Clin Sci 2007;112:517-525.
12. Loprinzi CL, Kugler J W, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, et al. Venlafaxine in management of hot fashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
13. Guttuso T Jr, Kurlan R, McDermott M P, Kieburtz K. Gabapentin's efects on hot fashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345.
14. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, et al. Nonhormonal therapies for menopausal hot fashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
15. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health 2010;2:123-135.
16. Swartzman LC, Edelberg R, Kemmann E. Impact of stress on objectively recorded menopausal hot fushes and on fush report bias. Health Psychol 1990;9:529-545.
17. Prior JC, Alojado N, McKay DW, Vigna YM. No adverse efects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. Obstet Gynecol 1994;83:24-28.
18. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot fash studies. J Clin Oncol 2001;19:4280-4290.
19. Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, et al. New-onset breast tenderness afer initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med 2009;169:1684-1691.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghof E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
21. Mather KJ, Norman EG, Prior JC, Elliott TG. Preserved forearm endothelial responses with acute exposure to progesterone: A randomized cross-over trial of 17-beta estradiol, progesterone, and 17-beta estradiol with progesterone in healthy menopausal women. J Clin Endocrinol Metab 2000;85:4644-4649.
22. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, Trillot N, et al.; Estrogen and Tromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
23. Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15 Suppl 1:11-17.
24. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with diferent hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107:103-111.
25. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
26. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Efects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-134.
27. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate efects in breast cells. Breast Cancer Res Treat 2012;131:49-63.
28. Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Ligniéres B. Infuences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785-791.
29. Foidart JM, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, de Lignières B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969.
30. Murkes D, Conner P, Leifand K, Tani E, Beliard A, Lundström E, Söderqvist G. Efects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188-1191.
31. Schüssler P, Kluge M, Yassouridis A, Dresler M, Held K, Zihl J, Steiger A. Progesterone reduces wakefulness in sleep EEG and has no efect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33:1124-1131.
32. Caufriez A, Leproult R, L'Hermite-Balériaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011;96:E614-E623.
33. Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N, Yun SC, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009;85:312-318.
34. Simon JA, Shangold MM, Andrews MC, Buster JC, Hodgen GD. Micronized progesterone therapy: the importance of route of administration and pharmacokinetics on clinical outcome. J Contracept Fertil Sex 1992;20:13-18.